Combination Therapy Shown As Effective For Higher-Risk MDS/AML Patients
A phase two study that investigated the potential of the drugs
azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two
therapies in combination may be an effective frontline treatment regimen
for patients with higher-risk forms of myelodysplastic syndrome and
acute myeloid leukemia.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Leukemia | Myelodysplastic Syndrome | Revlimid | Study